published meta-analysis   sensitivity analysis   studies

Colchicine plus rosuvastatin in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsGaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36] 0.81[0.48; 1.36]Gaitan-Duarte (Rosuvastatin plus colchicine), 202110%314NAnot evaluable deathsdetailed resultsGaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36] 0.81[0.48; 1.36]Gaitan-Duarte (Rosuvastatin plus colchicine), 202110%314NAnot evaluable mechanical ventilationdetailed resultsGaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06] 0.85[0.68; 1.06]Gaitan-Duarte (Rosuvastatin plus colchicine), 202110%276NAnot evaluable ICU admissiondetailed resultsGaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75] 0.99[0.56; 1.75]Gaitan-Duarte (Rosuvastatin plus colchicine), 202110%227NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-11-01 01:13 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 1102 - roots T: 290